
Trex Company Announces Departure of Chief Financial Officer
WINCHESTER, Va.--(BUSINESS WIRE)--Trex Company, Inc. (NYSE:TREX), the world's largest manufacturer of wood-alternative decking and railing and a leader in high-performance, low-maintenance outdoor living products, today announced that Brenda Lovcik has resigned as Senior Vice President and Chief Financial Officer (CFO) to accept a position in Minnesota, near to her family.
'We appreciate Brenda's contributions to the Trex Company and the financial experience she brought to our organization. Brenda has been a valuable member of our executive leadership team, and we wish her the very best in her future endeavors,' said Bryan Fairbanks, President and Chief Executive Officer (CEO).
Ms. Lovcik will continue to serve as CFO through August 5, 2025, at which time the CFO responsibilities at Trex will be assumed on an interim basis by Bryan Fairbanks. Mr. Fairbanks served as CFO from August 2015 until being named CEO and a member of the Board in April 2020.
Trex is pleased to reiterate its guidance for full year 2025 revenue growth of 5%-7% and Adjusted EBITDA margin to exceed 31% and is on track to achieve its second quarter revenue guidance of $370 million to $380 million.
The company has begun a search to identify the next CFO.
About Trex Company
For more than 30 years, Trex Company [NYSE: TREX] has invented, reinvented and defined the composite decking category. Today, the company is the world's #1 brand of sustainably made wood-alternative decking, and residential railing, as well as a leader in high performance, low-maintenance outdoor living products. Trex boasts the industry's strongest distribution network with products sold through more than 6,700 retail outlets across six continents. Through strategic licensing agreements, the company offers a comprehensive outdoor living portfolio that includes deck drainage, flashing tapes, LED lighting, outdoor kitchen components, pergolas, spiral stairs, fencing, lattice, cornhole and outdoor furniture – all marketed under the Trex ® brand. Based in Winchester, Va., Trex is proud to have been named America's Most Trusted ® Outdoor Decking ^ 5 Years in a Row (2021-2025). The company also holds a place on Barron's list of the 100 Most Sustainable U.S. Companies (2024 and 2025), was named one of America's Most Responsible Companies 2024 by Newsweek, ranked as one of the 100 Best ESG Companies by Investor's Business Daily, and named the Sustainable Brand Leader in the decking category by Green Builder Media for the 15 th consecutive year. For more information, visit Trex.com. You may also follow Trex on Facebook (trexcompany), Instagram (trexcompany), X (Trex_Company), LinkedIn (trex-company), TikTok (trexcompany), Pinterest (trexcompany) and Houzz (trex-company-inc), or view product and demonstration videos on the brand's YouTube channel (TheTrexCo).
Forward-Looking Statements
The statements in this press release regarding the Company's expected future performance and condition constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that could cause the Company's actual operating results to differ materially. Such risks and uncertainties include, but are not limited to: the extent of market acceptance of the Company's current and newly developed products; the costs associated with the development and launch of new products and the market acceptance of such new products; the sensitivity of the Company's business to general economic conditions; the impact of seasonal and weather-related demand fluctuations on inventory levels in the distribution channel and sales of the Company's products; the availability and cost of third-party transportation services for the Company's products and raw materials; the Company's ability to obtain raw materials, including scrap polyethylene, wood fiber, and other materials used in making our products, at acceptable prices; increasing inflation and tariffs in the macro-economic environment; the Company's ability to maintain product quality and product performance at an acceptable cost; the Company's ability to increase throughput and capacity to adequately match supply with demand; the level of expenses associated with warranty claims, product replacement and consumer relations expenses related to product quality; the highly competitive markets in which the Company operates; cyber-attacks, security breaches or other security vulnerabilities; the impact of current and upcoming data privacy laws and the EU General Data Protection Regulation and the related actual or potential costs and consequences; material adverse impacts from global public health pandemics and geopolitical conflicts; and material adverse impacts related to labor shortages or increases in labor costs. Documents filed with the U.S. Securities and Exchange Commission by the Company, including in particular its latest annual report on Form 10-K and quarterly reports on Form 10-Q, discuss some of the important factors that could cause the Company's actual results to differ materially from those expressed or implied in these forward-looking statements. The Company expressly disclaims any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
42 minutes ago
- Business Wire
WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊,請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱,在整個集體訴訟期內,被告做出了虛假和誤導性陳述及/或未揭露:(1)儘管聲稱對客戶需求有清晰預判,並將業務阻力歸咎於COVID相關產品的臨時性去庫存,但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象;(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品,但由於營運效率不彰,對West的利潤率造成了嚴重稀釋;(3)這些利潤率壓力引發了高昂重整活動的風險,包括West退出與長期客戶簽署的持續血糖監測(CGM)合約;以及(4)由於上述原因,被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱,當市場瞭解真實詳情後,投資人蒙受了損失。 現在怎麼辦:您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表,則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動,您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊,請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm:與Rosen Law Firm不同,一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者, Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構,並追究公司高階主管的違法行為責任。自成立以來,Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn: 、Twitter: 或Facebook: 上關注我們,以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。


Business Wire
an hour ago
- Business Wire
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.


Business Insider
2 hours ago
- Business Insider
Jefferies Sticks to Their Buy Rating for Halliburton (HAL)
Jefferies analyst Lloyd Byrne reiterated a Buy rating on Halliburton (HAL – Research Report) today and set a price target of $32.00. The company's shares closed yesterday at $20.57. Confident Investing Starts Here: Byrne covers the Energy sector, focusing on stocks such as Baker Hughes Company, Expand Energy, and Canadian Natural. According to TipRanks, Byrne has an average return of 18.1% and a 50.90% success rate on recommended stocks. In addition to Jefferies, Halliburton also received a Buy from Wells Fargo's Roger Read in a report issued on June 24. However, on June 26, RBC Capital maintained a Hold rating on Halliburton (NYSE: HAL). Based on Halliburton's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.42 billion and a net profit of $204 million. In comparison, last year the company earned a revenue of $5.8 billion and had a net profit of $606 million Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HAL in relation to earlier this year. Last month, Weiss Janet L, a Director at HAL bought 8,550.00 shares for a total of $169,119.00.